Basic characteristics of enrolled participants
| Variables | Control (240) | CHB (134) | LC (479) | p Value |
|---|---|---|---|---|
| Female/male | 61/179 | 34/100 | 126/353 | 0.956 |
| Age (year) | 50.6±9.69 | 48.9±8.04 | 50.8±10.8 | 0.163 |
| HBsAg-positive (yes/no) | 0/240 | 134/0 | 479/0 | – |
| HBeAg-positive (yes/no) | 0/240 | 66/68 | 184/295 | 0.024* |
| TP (g/L) | 71.6±3.79 | 67.3±6.83† | 62.9±8.48†* | <0.001 |
| ALB (g/L) | 46.2±3.17 | 37.4±5.95† | 33.2±5.61†* | <0.001 |
| TBIL (μmol/L) | 12 (6–49) | 21.5 (5–309)† | 31 (5–839)†* | <0.001 |
| ALT (U/L) | 17 (7–48) | 61 (9–1838)† | 29 (4–1882)†* | <0.001 |
| AST (U/L) | 19 (12–46) | 48 (16–1235)† | 40 (8–4094)†* | <0.001 |
| TG (mmol/L) | 1.08 (0.41–1.70) | 1.33 (0.44–4.14)† | 0.79 (0.3–3.59)†* | <0.001 |
| Tch (mmol/L) | 4.66 (2.40–5.86) | 4.04 (1.6–8.17)† | 2.89 (0.74–9.73)† | <0.001 |
| Cr (μmol/L) | 73 (39–100) | 65 (29–154)† | 66 (30–729)† | 0.002 |
| INR | 0.94±0.05 | 1.21±0.23† | 1.55±0.78†* | <0.001 |
| WCC (1012/L) | 5.6 (4.0–9.4) | 4.75 (2–12)† | 3.9 (0.8–32.8)†* | <0.001 |
| LMR | 5.30 (1.4–13.2) | 3.64 (0.65–9.61)† | 2.77 (0.27–18.25)†* | <0.001 |
| MELD score | – | 5.89 (0–23.63) | 9.89 (0–57.17) | <0.001* |
| Mortality (yes/no) | – | 1/133 | 92/387 | <0.001* |
Data were presented as mean±SD and median (range).
p Value: comparison among these three groups.
*LC group versus the CHB group.
†p Value <0.05 versus the control group.
ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHB, chronic hepatitis B; Cr, creatinine; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; INR, international normalised ratio; LC, liver cirrhosis; LMR, lymphocyte-to-monocyte ratio; MELD score, model for end-stage liver disease score; TB, total bilirubin; Tch, total cholesterol; TG, triglyceride; TP, total protein; WCC, white cell count.